Fexit B

The dose which the patient gets through the mouthpiece of the device is 180 mcg.

Beclometasone (Fexit B) contains 200 doses of finely powdered beclomethasone dipropionate mixed in a small quantity of lactose. The amount of drug received by the patient (180 mcg/dose) corresponds to that from 2 puffs of the freon-based beclomethasone inhalation aerosol with a metered dose of 100 mcg/dose. The dose to be inhaled is released from the container by pressing the device between the thumb and the forefinger. This is followed by inhalation through the device. As a result, beclomethasone dipropionate particles are transferred to their target, the lungs. Use of the Beclometasone (Fexit B) does not require coordination of actuation of the dose and inhalation.

Fusidic Acid (Fexit B) is a bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Fusidic Acid (Fexit B) A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.

Maintenance treatment of asthma as prophylactic therapy in adults and children (≥5 years). For asthma patients who require systemic corticosteroid administration where adding Beclometasone (Fexit B) dipropionate may reduce or eliminate the need for the systemic corticosteroids.

Beclometasone (Fexit B) dipropionate is not indicated for the relief of acute bronchospasm.

Fusidic Acid (Fexit B) is active in vitro against Staphylococcus aureus, most coagulase-negative staphylococci, Corynebacterium species, most clostridium species. Fusidic Acid (Fexit B) has no useful activity against enterococci or most Gram-negative bacteria (except Neisseria, Moraxella, Legionella pneumophila and Bacteroides fragilis). Fusidic Acid (Fexit B) is active in vitro and clinically against Mycobacterium leprae but has only marginal activity against Mycobacterium tuberculosis.

One important use of Fusidic Acid (Fexit B) clinically is its activity against methicillin-resistant Staphylococcus aureus. Many strains of MRSA remain sensitive to Fusidic Acid (Fexit B), but because there is a low genetic barrier to drug resistance (a single point mutation is all that is required), Fusidic Acid (Fexit B) must never be used on its own to treat serious MRSA infection and should be combined with another antimicrobial such as rifampicin.

Fusidic Acid (Fexit B) is often found in topical skin and eye preparations (e.g., Fucibet), a use which has been contested.

Beclomethasone is a steroid. It prevents the release of substances in the body that cause inflammation.

Beclomethasone nasal is used to treat nasal symptoms such as congestion, sneezing, and runny nose caused by seasonal or year-round allergies. The Beclometasone (Fexit B) brand of this medication is also used to keep nasal polyps from coming back after surgery to remove them.

Beclomethasone may also be used for purposes not listed in this medication guide.

Fusidic Acid (Fexit B) is a substance that is used to treat bacterial infections. It will not work for colds, flu, or other virus infections.

Fusidic Acid (Fexit B) is available only with your doctor's prescription.

Management of Chronic Asthma: Adults and Children >12 years: 100-400 mcg twice daily. Maximum: 1000 mcg twice daily.

Children (5-12 years): 100-200 mcg twice daily. Maximum: 200-400 mcg twice daily.

Prophylaxis of Asthma: Adults and Children >12 years: 50-200 mcg twice daily. Increase if necessary to maximum 400 mcg twice daily.

Children (5-12 years): The usual starting dose is 100 mcg twice daily. Depending on the severity of asthma, the daily dose may be increased up to 400 mcg administered in 2-4 divided doses.

When patient's symptoms remain under satisfactory control, the dose should be titrated to the lowest dose at which effective control of asthma is maintained.

Therapy in New Patients: Mild Asthma: 50-100 mcg twice daily.

Moderate Asthma: 100-200 mcg twice daily.

Severe Asthma: 200-400 mcg twice daily.

When switching a patient with well-controlled asthma from another corticosteroid inhaler, initially Beclometasone (Fexit B) 100 mcg puff should be prescribed for Beclometasone (Fexit B) dipropionate (CFC) or budesonide 200-250 mcg; fluticasone propionate 100 mcg.

When switching a patient with poorly-controlled asthma from another corticosteroid inhaler, initially Beclometasone (Fexit B) 100 mcg puff should be prescribed for Beclometasone (Fexit B) dipropionate (CFC) or budesonide or fluticasone propionate 100 mcg. The dose of Beclometasone (Fexit B) should be adjusted to response.

Use in the elderly or patients with hepatic or renal impairment: There are no special dosage recommendations for use in the elderly or in patients with hepatic or renal impairment.

Cream/Ointment: Apply to the affected area 2-3 times a day, generally for a period of 7 days.

Fusidic Acid (Fexit B) ointment can be used with or without a covering dressing.

Hypersensitivity to Beclometasone (Fexit B) diproprionate or to any of the excipients of Beclometasone (Fexit B).

Fusidic Acid (Fexit B) is contraindicated in patients with known hypersensitivity to this antibiotic. Fusidic Acid (Fexit B) is contraindicated in patients taking terfenadine, astemizole, or cisapride.

Topical Ery 2% Pads are contraindicated in those individuals who have shown hypersensitivity to any of its components.

Beclometasone (Fexit B) is used to treat runny nose, swelling and itching of the nose due to allergy (allergic rhinitis), hay fever and ulcerative colitis. Beclometasone (Fexit B) reduces inflammation, swelling and irritation in nose and helps to relieve itching, sneezing and blocked or runny nose. It is also used in asthma and ulcerative colitis.

Fusidic Acid (Fexit B) is used for treating various bacterial skin infections and some infections of bone, heart, lungs and eyes.

See also:
What other drugs will affect Beclometasone (Fexit B)?

Due to the very low plasma concentration achieved after inhaled dosing, clinically significant drug interactions are in general unlikely. Care should be taken when co-administering with known strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, nelfinavir, ritonavir) as there is a potential for increased systemic exposure to Beclometasone (Fexit B).

Fusidic Acid (Fexit B) use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity. In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient is receiving concomitant erythromycin therapy.

Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels. There have been reports of increased anticoagulant effects when erythromycin and oral anticoagulants were used concomitantly. Increased anticoagulation effects due to interactions of erythromycin with various oral anticoagulents may be more pronounced in the elderly.

Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.

Fusidic Acid (Fexit B) has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.

The use of erythromycin in patients concurrently taking drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these other drugs. There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole. Serum concentrations of drugs metabolized by the cytochrome P450 system should be monitored closely in patients concurrently receiving erythromycin.

Fusidic Acid (Fexit B) has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and astemizole when taken concomitantly. Rare cases of serious cardiovascular adverse events, including electrocardiographic QT/QTc interval prolongation, cardiac arrest, torsades de pointes, and other ventricular arrhythmias have been observed. In addition, deaths have been reported rarely with concomitant administration of terfenadine and erythromycin.

There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin. Fatalities have been reported.

Patients receiving concomitant lovastatin and erythromycin should be carefully monitored; cases of rhabdomyolysis have been reported in seriously ill patients.

See also:
What are the possible side effects of Beclometasone (Fexit B)?

Nasal Inhaler

In general, side effects in clinical studies have been primarily associated with the nasal mucous membranes.

Adverse reactions reported in controlled clinical trials and long-term open studies in patients treated with beclomethasone dipropionate nasal inhaler are described below.

Sensations of irritation and burning in the nose (11 per 100 patients) following the use of beclomethasone dipropionate nasal inhaler have been reported. Also, occasional sneezing attacks (10 per 100 adult patients) have occurred immediately following the use of the intranasal inhaler. This symptom may be more common in children. Rhinorrhea may occur occasionally (1 per 100 patients).

Localized infections of the nose and pharynx with Candida albicans have occurred rarely.

Transient episodes of epistaxis have been reported in 2 per 100 patients.

Rare cases of ulceration of the nasal mucosa and instances of nasal septum perforation have been spontaneously reported.

Reports of headache, light-headedness, dryness and irritation of the nose and throat, and unpleasant taste and smell have been received. There are rare reports of loss of taste and smell.

Rare instances of wheezing, cataracts, glaucoma and increased intraocular pressure have been reported following the intranasal application of aerosolized corticosteroids.

Rare cases of immediate and delayed hypersensitivity reactions, including urticaria, angioedema, rash, and bronchospasm, have been reported following the oral and intranasal inhalation of beclomethasone.

Systemic corticosteroid side effects were not reported during the controlled clinical trials. If recommended doses are exceeded, however, or if individuals are particularly sensitive, symptoms of hypercorticism (i.e., Cushing's syndrome, could occur).

Nasal Spray

In general, side effects in clinical studies have been primarily associated with irritation of the nasal mucous membranes. Rare cases of immediate and delayed hypersensitivity reactions, including urticaria, angioedema, rash, and bronchospasm, have been reported following the oral and intranasal inhalation of beclomethasone dipropionate.

Adverse reactions reported in controlled clinical trials and open studies in patients treated with beclomethasone dipropionate nasal spray are described below.

Mild nasopharyngeal irritation following the use of beclomethasone aqueous nasal spray has been reported in up to 24% of patients treated, including occasional sneezing attacks (about 4%) occurring immediately following use of the spray. In patients experiencing these symptoms, none had to discontinue treatment. The incidence of transient irritation and sneezing was approximately the same in the group of patients who received placebo in these studies, implying that these complaints may be related to vehicle components of the formulation.

Fewer than 5 per 100 patients reported headache, nausea, or lightheadedness following the use of beclomethasone dipropionate nasal spray. Fewer than 3 per 100 patients reported nasal stuffiness, nosebleeds, rhinorrhea, or tearing eyes.

Rare cases of ulceration of the nasal mucosa and instances of nasal septum perforation have been spontaneously reported.

Reports of dryness and irritation of the nose and throat, and unpleasant taste and smell have been received. There are rare reports of loss of taste and smell.

Rare instances of wheezing, cataracts, glaucoma, and increased intraocular pressure have been reported following the use of intranasal beclomethasone.

See also:
What are the possible side effects of Fusidic Acid (Fexit B)?

Occasionally hypersensitivity reactions eg, skin rashes, weak pain and irritation may occur. If these symptoms occur, discontinue Fusidic Acid (Fexit B).